(P078) Radiation Therapy in the Management of Carcinosarcoma of the Uterus

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Pelvic radiation reduces the risk of pelvic relapse in patients with MMMT and may be indicated with patients at high risk for pelvic recurrence, including patients with cervical involvement, heterologous elements, and stage III disease.

Jillian R. Gunther, MD, PhD, Eva N. Christensen, MD, PhD, Pamela K. Allen, PhD, Lois M. Ramondetta, MD, Anuja Jhingran, MD, Nicole D. Fleming, MD, Elizabeth Euscher, MD, Karen H. Lu, Patricia J. Eifel, MD, Ann H. Klopp, MD, PhD; UT MD Anderson Cancer Center; Radiation Oncology Associates

PURPOSE: Uterine mixed Müllerian tumor (MMMT) is often treated with multimodality therapy, including surgery, chemotherapy, vaginal cuff brachytherapy (VCB), and/or pelvic radiation. However, the indications for pelvic and vaginal cuff radiation are unclear. To investigate this, we reviewed our institutional experience with treatment of uterine MMMT.

METHODS: We performed a retrospective review of 155 women with stage I–III uterine carcinosarcoma who underwent total abdominal hysterectomy-bilateral salpingo-oophorectomy (TAH-BSO) at our institution between 1990 and 2011. Overall survival (OS), disease-specific survival (DSS), and pelvic relapse–free survival (PRFS) were calculated using the Kaplan-Meier method, with differences assessed using a log-rank test. Multivariate Cox proportional hazards regression analyses were performed to evaluate the influence of different factors on DSS and PRFS.

RESULTS: The study included patients with stage I (n = 98), II (n = 11), and III (n = 46) uterine MMMT. Median follow-up was 51 months (range: 2–278 mo). A total of 70 patients (45%) received chemotherapy (21 concurrent, 58 adjuvant, 9 both). Also, 108 patients (70%) received radiation therapy (RT); 35% of these patients received pelvic radiation, and 65% received pelvic radiation with or without additional brachytherapy. The 5-year OS for all patients was 48.6% (stage I, 53.8%; II, 30.0%; and III, 42.5%). The 5-year DSS was 57.17% (stage I, 60.88%; II, 44.44%; and III, 51.82%). The first site of recurrence was in the pelvis and/or para-aortic (PA) lymph nodes for 28 patients (44%), abdomen ± pelvis for 13 patients (21%), and distant for 22 patients (35%). On univariate analysis, lower rates of DSS were seen in patients aged ≥ 65 years (P = .001) and with hypertension (P = .03), higher tumor grade (P = .02), cervical involvement (P = .001), and lymphovascular space invasion (LVSI) (P = .004). On multivariate analysis, age ≥ 65 years (P = .001), cervical involvement (P = .03), and LVSI (P = .01) remained independently associated with lower DSS.

PRFS was higher in patients receiving pelvic radiation as compared with VCB or no radiation (88.3% at 5 yr for pelvic radiation vs 67.4% for VCB and 71.2% for no RT; P = .04). Among patients who did not receive pelvic radiation, cervical involvement (hazard ratio [HR] = 3.2; P = .03) and heterologous elements (HR = 2.9; P = .04) were associated with pelvic relapse. In stage III patients, pelvic radiation was associated with higher rates of 5-year PRFS (90.0% vs 55.5%; P = .046), DSS (64.6% vs 46.4%; P = .13) and OS (64.6% vs 34.0%; P = .04). 

CONCLUSIONS: Pelvic radiation reduces the risk of pelvic relapse in patients with MMMT and may be indicated with patients at high risk for pelvic recurrence, including patients with cervical involvement, heterologous elements, and stage III disease.

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Increasing age, higher Gleason scores, and higher pathologic stages are predictors of mortality in patients with prostate cancer, according to an expert from Dana-Farber Cancer Institute.
Clinical trials highlight benefits, including radiographic progression-free survival following treatment with radioligand 177Lu-PSMA-617 in pretreated patients with metastatic castration-resistant prostate cancer.
Early data from ongoing clinical trials suggest the potential safety and efficacy of novel radium-223 combinations as treatment for metastatic castration-resistant prostate cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.
The use of palliative care in ovarian cancer resulted in a decrease in overall readmissions and index hospitalization costs.
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Related Content